Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/18503494http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/18503494http://www.w3.org/2000/01/rdf-schema#comment"

Background

Anti-CD25 and mycophenolate mofetil (MMF) treatment of patients with new-onset diabetes is currently being tested as one of the trials in TrialNet. We tested the effectiveness of MMF and anti-CD25 in preventing autoimmune diabetes in the diabetes-resistant biobreeding (DRBB) rat.

Methods

Autoimmune diabetes in the DRBB rat was induced with a Treg cell depletion regimen starting at 24-26 d of age. Treatment was started on the first day of the depletion regimen in the following groups: (i) control (vehicle); (ii) MMF 25 mg/kg/d intramuscularly daily for 8 wk; (iii) anti-CD25 0.8 mg/kg/d intraperitoneally 5 d/wk for 3 wk; and (iv) combination of MMF and anti-CD25. In a second set of experiments, treatments were started on day 5 of the depletion regimen (delayed treatment) with groups 1, 3, and 4. Rats that had diabetes-free survival for at least 30 d after the treatment was stopped underwent a second Treg depletion (redepletion).

Results

In each of the three treatment groups (n = 10/group), onset of diabetes was delayed or prevented in 20, 40 and 80% in groups 2, 3, and 4, respectively. After redepletion, diabetes-free survival was unchanged in group 2 and decreased to 10 and 30% in groups 3 and 4, respectively. With delayed treatment, groups 3 and 4 had 33 and 50% diabetes-free survival that decreased to 0 and 33% after redepletion.

Summary

MMF and anti-CD25 alone or in combination are effective in delaying and preventing diabetes in the DRBB rat especially if treatment is started before stimulation and expansion of the autoreactive T cells."xsd:string
http://purl.uniprot.org/citations/18503494http://purl.org/dc/terms/identifier"doi:10.1111/j.1399-5448.2008.00417.x"xsd:string
http://purl.uniprot.org/citations/18503494http://purl.uniprot.org/core/author"Moore W.V."xsd:string
http://purl.uniprot.org/citations/18503494http://purl.uniprot.org/core/author"Tong P.Y."xsd:string
http://purl.uniprot.org/citations/18503494http://purl.uniprot.org/core/author"Kover K.L."xsd:string
http://purl.uniprot.org/citations/18503494http://purl.uniprot.org/core/author"Ugrasbul F."xsd:string
http://purl.uniprot.org/citations/18503494http://purl.uniprot.org/core/date"2008"xsd:gYear
http://purl.uniprot.org/citations/18503494http://purl.uniprot.org/core/name"Pediatr Diabetes"xsd:string
http://purl.uniprot.org/citations/18503494http://purl.uniprot.org/core/pages"596-601"xsd:string
http://purl.uniprot.org/citations/18503494http://purl.uniprot.org/core/title"Prevention of diabetes: effect of mycophenolate mofetil and anti-CD25 on onset of diabetes in the DRBB rat."xsd:string
http://purl.uniprot.org/citations/18503494http://purl.uniprot.org/core/volume"9"xsd:string
http://purl.uniprot.org/citations/18503494http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/18503494
http://purl.uniprot.org/citations/18503494http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/18503494
http://purl.uniprot.org/uniprot/#_P26897-mappedCitation-18503494http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/18503494
http://purl.uniprot.org/uniprot/P26897http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/18503494